Latest Oncogenex Pharmaceuticals Inc (OGXI) Headlines
Narrower-than-Expected Loss at OncoGenex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:34PM CDT
OncoGenex Pharma reported a loss of 45 cents per share in the 4Q13, narrower than the Zacks Consensus Estimate of a loss of 62 cents.
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2013
CNW Group - Tue Mar 11, 3:00PM CDT
Conference call to be held on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time
OncoGenex Pharmaceutical Has Returned 49.7% Since SmarTrend Recommendation (OGXI)
Comtex SmarTrend(R) - Fri Mar 07, 9:37AM CST
SmarTrend identified an Uptrend for OncoGenex Pharmaceutical (NASDAQ:OGXI) on November 21st, 2013 at $7.97. In approximately 4 months, OncoGenex Pharmaceutical has returned 49.70% as of today's recent price of $11.93.
OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:51AM CST
OncoGenex Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 7% on the day.
3 Big-Volume Stocks in Breakout Territory
at The Street - Thu Mar 06, 5:00AM CST
These stocks trading on unusual volume are within range of triggering breakout trades.
Concise Analysis of the International Bolus Injectors Market, 2014 - 2024
M2 - Tue Mar 04, 6:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/jpbd3g/bolus_injectors) has announced the addition of the "Concise Analysis of the International Bolus Injectors Market, 2014 - 2024" report to their offering. The injectable drug delivery market holds significant potential for the future. From conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the injectable drug delivery devices market has come a long way. Taking the concept of self-injectors to a new stratum, Bolus Injectors' have surfaced recently. Also known as non-insulin patch pumps, these devices not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry. One of the main drivers for the perceived growth of bolus injectors is the large number of biologics currently under development. A majority of these molecules are highly viscous and are required to be delivered in volumes of greater than 1 ml. The absence of devices which can safely administer these drugs is currently a big unmet need in the market. However, the early signs are encouraging. Despite the uncertainties related to the device development and approval, many companies are investing time, money and resources to develop novel devices. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Overview And Market Background 4. Target Drugs For Bolus Injectors 5. Product Profiles 6. Market Size And Forecast 7. Swot Analysis 8. Company Profiles 9. Interview Transcripts 10. Conclusion 11. Appendix 1: Tables 12. Appendix 2: List Of Companies Companies Mentioned: - AbbVie - Abbott - BMS - Boehringer Ingelheim - Calando Pharmaceuticals - Calibra Medical - Dekkun - Denderon - Eisai - Elcam Medical - Eli Lilly - Five Prime Therapeutics - Future Injection Technologies - Genentech - Genethon - Isis Pharmaceuticals - J&J - Janssen Biotech - Kyowa Hakko Kirin - Lincoln Medical Limited - MacroGenics - Nuron Biotech - Octapharma - OncoGenex Technologies - Pfizer - PhaseBio Pharmaceuticals - Roche - SteadyMed Therapeutics - Synageva BioPharma - TaiMed Biologics - Takeda Pharmaceuticals - VBL Therapeutics - West Pharmaceutical Services - Xbiotech - Ypsomed - ZZ Biotech For more information visit http://www.researchandmarkets.com/research/jp..._injectors
Shares of OGXI Up 45.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 28, 9:09AM CST
SmarTrend identified an Uptrend for OncoGenex Pharmaceutical (NASDAQ:OGXI) on November 21st, 2013 at $7.97. In approximately 3 months, OncoGenex Pharmaceutical has returned 45.61% as of today's recent price of $11.61.
OncoGenex to Report Financial Results for Fourth Quarter and Year-Ended 2013 on March 11, 2014
PR Newswire - Tue Feb 25, 5:30AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and year-ended 2013 financial results will be released on Tuesday, March 11, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results, development programs and a general business update.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
47.9% Return Seen to Date on SmarTrend OncoGenex Pharmaceutical Call (OGXI)
Comtex SmarTrend(R) - Thu Feb 20, 4:45PM CST
SmarTrend identified an Uptrend for OncoGenex Pharmaceutical (NASDAQ:OGXI) on November 21st, 2013 at $7.97. In approximately 3 months, OncoGenex Pharmaceutical has returned 47.93% as of today's recent price of $11.79.
Pipeline Progress at OncoGenex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 3:45PM CST
OncoGenex announced that the number of pre-determined events required for final analysis of custirsen has been reached in the phase III SYNERGY study
OncoGenex Pharmaceutical Up 43.7% Since SmarTrend Uptrend Call (OGXI)
Comtex SmarTrend(R) - Thu Feb 13, 10:59AM CST
SmarTrend identified an Uptrend for OncoGenex Pharmaceutical (NASDAQ:OGXI) on November 21st, 2013 at $7.97. In approximately 3 months, OncoGenex Pharmaceutical has returned 43.73% as of today's recent price of $11.46.
Global Hospital Information Systems (HIS) Market 2014-2018
PR Newswire - Wed Feb 12, 5:40AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
OncoGenex Pharmaceuticals (OGXI) Jumps: Stock Rises 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 8:25AM CST
OncoGenex Pharmaceuticals was a big mover last session, with shares rising nearly 6%.
OncoGenex Announces Target Number of Events Reached in Phase 3 SYNERGY Trial of Custirsen in Metastatic Castrate-Resistant Prostate Cancer
CNW Group - Tue Feb 11, 5:01AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the pre-specified number of events required for final analysis of the Phase 3 SYNERGY trial has been reached.
32.6% Return Seen to Date on SmarTrend OncoGenex Pharmaceutical Call (OGXI)
Comtex SmarTrend(R) - Thu Feb 06, 9:38AM CST
SmarTrend identified an Uptrend for OncoGenex Pharmaceutical (NASDAQ:OGXI) on November 21st, 2013 at $7.97. In approximately 3 months, OncoGenex Pharmaceutical has returned 32.62% as of today's recent price of $10.57.
OncoGenex to Present at Leerink Global Healthcare Investor Conference
CNW Group - Thu Feb 06, 5:30AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 8:50 a.m. ET at the Waldorf Astoria Hotel in New York City.
Narrower-than-Expected Loss at OncoGenex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 12, 12:34PM CDT
OncoGenex Pharma reported a loss of 45 cents per share in the 4Q13, narrower than the Zacks Consensus Estimate of a loss of 62 cents.
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2013
CNW Group - Tue Mar 11, 3:00PM CDT
Conference call to be held on Tuesday, March 11, 2014 at 4:30 p.m. Eastern Time
OncoGenex Pharmaceutical Has Returned 49.7% Since SmarTrend Recommendation (OGXI)
Comtex SmarTrend(R) - Fri Mar 07, 9:37AM CST
SmarTrend identified an Uptrend for OncoGenex Pharmaceutical (NASDAQ:OGXI) on November 21st, 2013 at $7.97. In approximately 4 months, OncoGenex Pharmaceutical has returned 49.70% as of today's recent price of $11.93.
OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 6.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 7:51AM CST
OncoGenex Pharmaceuticals, Inc. was a big mover last session, as its shares rose nearly 7% on the day.
3 Big-Volume Stocks in Breakout Territory
at The Street - Thu Mar 06, 5:00AM CST
These stocks trading on unusual volume are within range of triggering breakout trades.
Concise Analysis of the International Bolus Injectors Market, 2014 - 2024
M2 - Tue Mar 04, 6:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/jpbd3g/bolus_injectors) has announced the addition of the "Concise Analysis of the International Bolus Injectors Market, 2014 - 2024" report to their offering. The injectable drug delivery market holds significant potential for the future. From conventional syringes with vials and painful needles to the modern-day pre-filled syringes, pen-injectors, needle free injectors and auto-injectors, the injectable drug delivery devices market has come a long way. Taking the concept of self-injectors to a new stratum, Bolus Injectors' have surfaced recently. Also known as non-insulin patch pumps, these devices not only offer a range of benefits to the end users but also provide a number of additional benefits to other stakeholders in the industry. One of the main drivers for the perceived growth of bolus injectors is the large number of biologics currently under development. A majority of these molecules are highly viscous and are required to be delivered in volumes of greater than 1 ml. The absence of devices which can safely administer these drugs is currently a big unmet need in the market. However, the early signs are encouraging. Despite the uncertainties related to the device development and approval, many companies are investing time, money and resources to develop novel devices. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Overview And Market Background 4. Target Drugs For Bolus Injectors 5. Product Profiles 6. Market Size And Forecast 7. Swot Analysis 8. Company Profiles 9. Interview Transcripts 10. Conclusion 11. Appendix 1: Tables 12. Appendix 2: List Of Companies Companies Mentioned: - AbbVie - Abbott - BMS - Boehringer Ingelheim - Calando Pharmaceuticals - Calibra Medical - Dekkun - Denderon - Eisai - Elcam Medical - Eli Lilly - Five Prime Therapeutics - Future Injection Technologies - Genentech - Genethon - Isis Pharmaceuticals - J&J - Janssen Biotech - Kyowa Hakko Kirin - Lincoln Medical Limited - MacroGenics - Nuron Biotech - Octapharma - OncoGenex Technologies - Pfizer - PhaseBio Pharmaceuticals - Roche - SteadyMed Therapeutics - Synageva BioPharma - TaiMed Biologics - Takeda Pharmaceuticals - VBL Therapeutics - West Pharmaceutical Services - Xbiotech - Ypsomed - ZZ Biotech For more information visit http://www.researchandmarkets.com/research/jp..._injectors
Shares of OGXI Up 45.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 28, 9:09AM CST
SmarTrend identified an Uptrend for OncoGenex Pharmaceutical (NASDAQ:OGXI) on November 21st, 2013 at $7.97. In approximately 3 months, OncoGenex Pharmaceutical has returned 45.61% as of today's recent price of $11.61.
OncoGenex to Report Financial Results for Fourth Quarter and Year-Ended 2013 on March 11, 2014
PR Newswire - Tue Feb 25, 5:30AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's fourth quarter and year-ended 2013 financial results will be released on Tuesday, March 11, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results, development programs and a general business update.
Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!
at The Street - Fri Feb 21, 8:03AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
47.9% Return Seen to Date on SmarTrend OncoGenex Pharmaceutical Call (OGXI)
Comtex SmarTrend(R) - Thu Feb 20, 4:45PM CST
SmarTrend identified an Uptrend for OncoGenex Pharmaceutical (NASDAQ:OGXI) on November 21st, 2013 at $7.97. In approximately 3 months, OncoGenex Pharmaceutical has returned 47.93% as of today's recent price of $11.79.
Pipeline Progress at OncoGenex - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 3:45PM CST
OncoGenex announced that the number of pre-determined events required for final analysis of custirsen has been reached in the phase III SYNERGY study
OncoGenex Pharmaceutical Up 43.7% Since SmarTrend Uptrend Call (OGXI)
Comtex SmarTrend(R) - Thu Feb 13, 10:59AM CST
SmarTrend identified an Uptrend for OncoGenex Pharmaceutical (NASDAQ:OGXI) on November 21st, 2013 at $7.97. In approximately 3 months, OncoGenex Pharmaceutical has returned 43.73% as of today's recent price of $11.46.
Global Hospital Information Systems (HIS) Market 2014-2018
PR Newswire - Wed Feb 12, 5:40AM CST
Reportlinker.com announces that a new market research report is available in its catalogue:
OncoGenex Pharmaceuticals (OGXI) Jumps: Stock Rises 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 8:25AM CST
OncoGenex Pharmaceuticals was a big mover last session, with shares rising nearly 6%.
OncoGenex Announces Target Number of Events Reached in Phase 3 SYNERGY Trial of Custirsen in Metastatic Castrate-Resistant Prostate Cancer
CNW Group - Tue Feb 11, 5:01AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today announced that the pre-specified number of events required for final analysis of the Phase 3 SYNERGY trial has been reached.
32.6% Return Seen to Date on SmarTrend OncoGenex Pharmaceutical Call (OGXI)
Comtex SmarTrend(R) - Thu Feb 06, 9:38AM CST
SmarTrend identified an Uptrend for OncoGenex Pharmaceutical (NASDAQ:OGXI) on November 21st, 2013 at $7.97. In approximately 3 months, OncoGenex Pharmaceutical has returned 32.62% as of today's recent price of $10.57.
OncoGenex to Present at Leerink Global Healthcare Investor Conference
CNW Group - Thu Feb 06, 5:30AM CST
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, President and Chief Executive Officer, will provide a corporate presentation at the Leerink Global Healthcare Conference on Wednesday, February 12, 2014 at 8:50 a.m. ET at the Waldorf Astoria Hotel in New York City.
